Three Brands of OTC Naloxone Now Exist. Competition Alone Won't Save Lives.

On June 16, the FDA cleared Rextovy — Amphastar Pharmaceuticals’ 4mg naloxone hydrochloride nasal spray — for over-the-counter sale without a prescription, pharmacist consultation, or physician visit. It is the same active ingredient and same dose as Narcan, the original OTC naloxone that cleared in 2023. Rextovy is the third such product on shelves, after Narcan and RiVive.

The FDA’s announcement quoted the now-familiar statistic: overdose deaths have fallen from a peak of 111,451 in the 12-month period ending August 2023 to 68,632 in the period ending December 2025. Expanded naloxone access is part of that story. The agency’s position — and the position of every major public health organization — is that more brands mean more availability, more competition that may reduce prices, and more supply-chain resilience if any single manufacturer has production problems.

That’s all true. But “available over the counter” and “in the hands of the person who needs it” are not the same thing. The distribution problem hasn’t been solved by making naloxone prescription-free. In rural Arizona, in tribal communities, in the neighborhoods where overdose deaths are still rising, the nearest pharmacy that stocks any naloxone — Narcan, RiVive, or now Rextovy — is not always within reach. A third brand on a CVS shelf in Scottsdale doesn’t get naloxone to a 22-year-old using alone in a group home in Yuma.

The harm reduction organizations that have actually moved naloxone at scale — community health workers going door to door in public housing, needle exchange vans, emergency department distribution programs — are the distribution channel that matters most for the populations experiencing the most deaths. Those organizations run on grant funding. That funding is under active federal review.

The multiplication of OTC brands is unambiguously good. The pretense that it closes the distribution gap is the part that warrants scrutiny. The drug can be bought without a prescription by anyone who walks into a pharmacy. The people dying in Maricopa County’s highest-overdose zip codes are, in many cases, not walking into pharmacies.

Rextovy’s approval is a useful addition to an incomplete solution. The incomplete part is the part that needs attention.

---

Follow harm reduction policy and the opioids series for ongoing coverage of naloxone access and overdose prevention.